zemplar 5 mcg ml inj sol 5x1ml - søkeresultat

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

zemplar 2 mikrogram/ml injektionsvätska, lösning

abbvie ab - parikalcitol - injektionsvätska, lösning - 2 mikrogram/ml - parikalcitol 2 mikrog aktiv substans; propylenglykol hjälpämne; etanol, vattenfri hjälpämne - parikalcitol

USA - engelsk - NLM (National Library of Medicine)

zemplar- paricalcitol injection, solution

abbvie inc. - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol 2 ug in 1 ml - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (ckd) on dialysis. zemplar is contraindicated in patients with: - hypercalcemia [see warnings and precautions ( 5.1 )] - vitamin d toxicity [see warnings and precautions ( 5.1 )] - known hypersensitivity to paricalcitol or any of the inactive ingredients in zemplar. hypersensitivity adverse reactions have been reported [e.g., angioedema (including laryngeal edema) and urticaria] [see adverse reactions ( 6.2 )] . risk summary limited data with zemplar in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy (see clinical considerations ) . in animal reproduction studies, slightly increased embryofetal loss was observed in pregnant rats and rabbits administered paricalcitol intravenously during the period of organogenes

Sveits - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

zemplar 5 ug/1ml injektionslösung

abbvie ag - paricalcitolum - injektionslösung - paricalcitolum 5 µg, ethanolum 170 mg, propylenglycolum 310 mg, aqua ad iniectabile ad solutionem pro 1 ml. - behandlung des sekundären hyperparathyreoidismus - synthetika

Sveits - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

zemplar 10 ug/2ml injektionslösung

abbvie ag - paricalcitolum - injektionslösung - paricalcitolum 10 µg, ethanolum 340 mg, propylenglycolum 620 mg, aqua ad iniectabile ad solutionem pro 2 ml. - behandlung des sekundären hyperparathyreoidismus - synthetika

Sveits - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

zemplar 2 ug/1ml injektionslösung

abbvie ag - paricalcitolum - injektionslösung - paricalcitolum 2 µg, ethanolum 170 mg, propylenglycolum 310 mg, aqua ad iniectabile ad solutionem pro 1 ml. - behandlung des sekundären hyperparathyreoidismus - synthetika